Berkshire Hathaway is deploying its $344B cash pile into undervalued stocks like UnitedHealth, while trimming Apple and BAC. See why BRK.A stock is a
Author: techrossm
Investors: This Is Warren Buffett’s No. 1 Index Fund Recommendation — and It Could Potentially Make You a Millionaire
With countless funds to choose from, though, it can be challenging to find the right fit. While everyone’s situation is different, there’s one investment
This Under-the-Radar AI Stock Could Double Your Money by 2028
Consider Upstart Holdings ( UPST 0.45%). The AI-based lending platform was a market favorite before its business seemed to implode, and investors have lost
Don’t Buy TQQQ After A Big Run Higher: Signs Of Market Top
ProShares UltraPro QQQ’s 3x leverage can amplify losses significantly if bought near a market top; August conditions suggest caution.
Navigating Thematic Investing With THRO
Leveraging artificial intelligence, portfolio managers of iShares U.S. Thematic Rotation Active ETF seek to identify emerging themes and the companies that could be positioned
Stock Market News, Aug. 15, 2025: Dow Hits Intraday Record, Boosted by UnitedHealth
Intel rallies as U.S. discusses taking stake in chip maker …
Morgan Stanley Preferred Stock To Benefit From Fed Funds Rate Reduction
Morgan Stanley 4.250% Depositary Shares Non-Cumulative Preferred Stock, Series O offers a compelling risk-reward profile in the current macro environment. Read the analysis here.
Stock Tips: Which picks are as ‘safe as houses’ this week? Maybe… houses?
It’s no easy gig analysing share prices and company performance but someone’s got to do it. Two experts from our … Read More The
It’s dividend time! — And time to let go: Money Talks
Money Talks columnist Darnell Mayberry closes the book on his years-long dividend investing strategy by selling his last individual stocks, shifting entirely to index
Eli Lilly Vs. Novo Nordisk: Correction Overly Done – GLP-1 Market Leadership/ Robust Pipelines Ahead
Novo Nordisk’s (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced return prospects. See more.